Dianthus Therapeutics (DNTH) PT Raised to $66 at Jefferies, 'We believe DNTH is undervalued'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DNTH Hot Sheet
Rating Summary:
18 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 13
Join SI Premium – FREE
Jefferies analyst Maury Raycroft raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $66.00 (from $51.00) while maintaining a Buy rating.
The analyst comments "We believe DNTH is undervalued at ~$580M EV following (+)ve de-risking gMG ph.II data based on est $2B peak sales in gMG, CIDP, & MMN. Updates from maturing OLE can derisk pot'l monthly dosing. 2026 will be catalyst-rich: 1) ARGX's DM ph.II 1H26; 2) CIDP ph.III interim responder analysis 2H26; 3) MMN ph.II top-line 2H26; 4) 2H26 pivotal readouts from SNY (CIDP) & ARGX (MMN). PT to $66 (vs prior $51)."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- SharkNinja (SN) PT Raised to $300 at Jefferies
- ArcBest Corp (ARCB) PT Raised to $175 at Citi
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsRelated Entities
Jefferies & Co, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
